» Articles » PMID: 25760441

Establishment of HSV1 Latency in Immunodeficient Mice Facilitates Efficient in Vivo Reactivation

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2015 Mar 12
PMID 25760441
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The establishment of latent infections in sensory neurons is a remarkably effective immune evasion strategy that accounts for the widespread dissemination of life long Herpes Simplex Virus type 1 (HSV1) infections in humans. Periodic reactivation of latent virus results in asymptomatic shedding and transmission of HSV1 or recurrent disease that is usually mild but can be severe. An in-depth understanding of the mechanisms regulating the maintenance of latency and reactivation are essential for developing new approaches to block reactivation. However, the lack of a reliable mouse model that supports efficient in vivo reactivation (IVR) resulting in production of infectious HSV1 and/or disease has hampered progress. Since HSV1 reactivation is enhanced in immunosuppressed hosts, we exploited the antiviral and immunomodulatory activities of IVIG (intravenous immunoglobulins) to promote survival of latently infected immunodeficient Rag mice. Latently infected Rag mice derived by high dose (HD), but not low dose (LD), HSV1 inoculation exhibited spontaneous reactivation. Following hyperthermia stress (HS), the majority of HD inoculated mice developed HSV1 encephalitis (HSE) rapidly and synchronously, whereas for LD inoculated mice reactivated HSV1 persisted only transiently in trigeminal ganglia (Tg). T cells, but not B cells, were required to suppress spontaneous reactivation in HD inoculated latently infected mice. Transfer of HSV1 memory but not OVA specific or naïve T cells prior to HS blocked IVR, revealing the utility of this powerful Rag latency model for studying immune mechanisms involved in control of reactivation. Crossing Rag mice to various knockout strains and infecting them with wild type or mutant HSV1 strains is expected to provide novel insights into the role of specific cellular and viral genes in reactivation, thereby facilitating identification of new targets with the potential to block reactivation.

Citing Articles

A fur plucking model to study herpes simplex virus reactivation and recurrent disease.

Philip D, Goins N, Lazear H mSphere. 2024; 9(10):e0078323.

PMID: 39382285 PMC: 11520289. DOI: 10.1128/msphere.00783-23.


The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity.

Cleaver J, Jeffery K, Klenerman P, Lim M, Handunnetthi L, Irani S Brain. 2023; 147(4):1130-1148.

PMID: 38092513 PMC: 10994539. DOI: 10.1093/brain/awad419.


B cells going viral in the CNS: Dynamics, complexities, and functions of B cells responding to viral encephalitis.

Cardani-Boulton A, Boylan B, Stetsenko V, Bergmann C Immunol Rev. 2022; 311(1):75-89.

PMID: 35984298 PMC: 9804320. DOI: 10.1111/imr.13124.


Robust anti-SARS-CoV2 single domain antibodies cross neutralize multiple viruses.

Singh S, Dahiya S, Singh Y, Beeton K, Jain A, Sarkar R iScience. 2022; 25(7):104549.

PMID: 35702569 PMC: 9181070. DOI: 10.1016/j.isci.2022.104549.


Resolution of herpes simplex virus reactivation in vivo results in neuronal destruction.

Doll J, Hoebe K, Thompson R, Sawtell N PLoS Pathog. 2020; 16(3):e1008296.

PMID: 32134994 PMC: 7058292. DOI: 10.1371/journal.ppat.1008296.


References
1.
Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K . Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. J Virol. 1999; 73(6):5196-200. PMC: 112570. DOI: 10.1128/JVI.73.6.5196-5200.1999. View

2.
Tan I, McArthur J, Venkatesan A, Nath A . Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology. 2012; 79(21):2125-32. PMC: 3511927. DOI: 10.1212/WNL.0b013e3182752ceb. View

3.
Stranska R, Schuurman R, Nienhuis E, Goedegebuure I, Polman M, Weel J . Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol. 2004; 32(1):7-18. DOI: 10.1016/j.jcv.2004.04.002. View

4.
Frobert E, Burrel S, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno J . Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France. Antiviral Res. 2014; 111:36-41. DOI: 10.1016/j.antiviral.2014.08.013. View

5.
van Velzen M, van de Vijver D, van Loenen F, Osterhaus A, Remeijer L, Verjans G . Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J Infect Dis. 2013; 208(9):1359-65. DOI: 10.1093/infdis/jit350. View